The European Medicines Agency's Committee for Medicinal Products for Human Use made a recommendation in favor of Pfizer Inc.'s Lifmior to treat rheumatoid arthritis and other forms of arthritis, as well as plaque psoriasis.

The drug is identical to Amgen's Enbrel, which was authorized in the EU in 2000. Lifmior is still subject to approval by the European Commission.